Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Jun 30, 2025
Revenue increased in the current quarter. The growth was driven by higher product sales.
Key takeaway
Quarter ended Jun 30, 2025 · FY2025 Q2
Revenue increased in the current quarter. The growth was driven by higher product sales.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3B
Revenue reported for this quarter.
Quarter-over-quarter
+7.0%
Change from the immediately preceding quarter.
Year-over-year
+12.1%
Change from the comparable year-ago quarter.
Trailing four quarters
$11.4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2024 | $2.8B | +11.6% |
| Dec 31, 2024 | $2.9B | +15.7% |
| Mar 31, 2025 | $2.8B | +3.0% |
| Jun 30, 2025 | $3B | +12.1% |
Revenue performance
Total revenue rose compared to the immediately preceding quarter and also improved versus the same quarter one year earlier.
Quarterly comparison
Revenue was higher than the prior quarter and exceeded the level reported a year ago. The sequential gain was solid, while the year-over-year increase was notably stronger.
What to watch
Monitor whether the pace of revenue growth can persist given the recent strong comparisons.